AI & ML News

Qure.ai Partners with Project Data Sphere for Cancer Care Using AI

Jon McDunn, PhD, President, Project Data Sphere.

Collaboration Aims to Enhance Efficiency in Assessing Cancer Treatments, Improving Patient Care Quality

Qure.ai  and Project Data Sphere Sphere announced their partnership to augment tumor assessments using AI-enabled solutions for clinical trials and cancer care. The collaboration aims to increase efficiency and consistency in evaluating the effectiveness of cancer treatments, ultimately improving the quality of care for patients.

The focus of this collaboration is autoRECIST, a product of Project Data Sphere’s Images and Algorithms program. The program, initiated in consultation with the U.S. Food and Drug Administration, includes stakeholders and experts from across the pharmaceutical industry and academia. In collaboration with Qure.ai, autoRECIST will address the critical need for automating and standardizing tumor response assessments in medical imaging to enhance cancer treatment and research. Rooted in current imaging guidelines, this AI clinical tool will aid radiologists in the detection, selection, measuring and tracking of lesions using defined criteria.

We are excited to enter into this collaboration with Qure to deliver tools that will streamline imaging-based tumor burden measurements, an important part of both clinical trials and routine care for cancer patients.”

Jon McDunn, PhD, President, Project Data Sphere.

autoRECIST can improve clinical trials and cancer treatments through:

  • Enhanced efficiency and improved accuracy through the automation of analyzing medical images (such as CT scans) and reducing variability when measuring tumor size and changes over time. 
  •  Faster decision-making in the assessment of tumor response, which enables researchers and clinicians to quickly determine if a treatment is effective or if changes in care are required.

This collaboration enables the sharing of unique insights, advanced methodologies and access to a broader network of industry leaders, further enriching the development of the autoRECIST solution.

“We are excited to enter into this collaboration with Qure to deliver tools that will streamline imaging-based tumor burden measurements, an important part of both clinical trials and routine care for cancer patients.” said Jon McDunn, PhD, President, Project Data Sphere.

This collaboration signifies a concerted effort by Qure.ai and Project Data Sphere to make substantial advancements in cancer care and elevate patient outcomes. The integration of AI technology into the evaluation process holds the potential to reshape the landscape of cancer clinical trials and generate more effective treatments for those affected by cancer.

Related posts

Canon India with JIM enhances its Training Program Under Skill India Initiative

enterpriseitworld

IFS to acquire Copperleaf

enterpriseitworld

Navigating the Deepfakes Challenge with Proactive measures

enterpriseitworld
x